Status:
UNKNOWN
Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Collaborating Sponsors:
CIRBA, Abidjan, Ivory Coast
SEREFO, Bamako, Mali
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
Main objective The main objective of the study is to assess the virological efficacy of a Dolutegravir-based first-line ART in use under real-life conditions in national programs in resource-limited s...
Detailed Description
Antiretroviral therapy (ART) has dramatically changed the pronostic of HIV/AIDS infection over the last 20 years, by reducing the mortality and morbibidity associted with the infection. This is mostly...
Eligibility Criteria
Inclusion
- Aged 18 years or over.
- Infected with HIV-1.
- On an NNRTI-based first-line for at least 6 months.
- Initiating a new 1st line ART based on DTG according to national recommendations.
- Agree to participate in the study and provide free, written and informed consent.
Exclusion
- Infection with HIV-2 or HIV1+2.
- Ongoing participation in another virological study on HIV infection
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
603 Patients enrolled
Trial Details
Trial ID
NCT05312918
Start Date
May 1 2022
End Date
October 1 2024
Last Update
April 6 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CIRBA
Abidjan, Côte d’Ivoire
2
SEREFO
Bamako, Mali
3
Biolim/Fss/Ul
Lomé, Togo